Cargando…

Immunologic aspect of ovarian cancer and p53 as tumor antigen

Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Nijman, HW, Lambeck, A, van der Burg, SH, van der Zee, AGJ, Daemen, T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243238/
https://www.ncbi.nlm.nih.gov/pubmed/16164749
http://dx.doi.org/10.1186/1479-5876-3-34
_version_ 1782125629901111296
author Nijman, HW
Lambeck, A
van der Burg, SH
van der Zee, AGJ
Daemen, T
author_facet Nijman, HW
Lambeck, A
van der Burg, SH
van der Zee, AGJ
Daemen, T
author_sort Nijman, HW
collection PubMed
description Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit significant immune responses against their tumor. In this review the knowledge obtained thus far on the interaction of ovarian cancer tumor cells and the immune system is discussed. Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. Based on the increased knowledge on the role of the immune system in ovarian cancer major improvements are to be expected of immunotherapy based treatment of this disease.
format Text
id pubmed-1243238
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-12432382005-10-07 Immunologic aspect of ovarian cancer and p53 as tumor antigen Nijman, HW Lambeck, A van der Burg, SH van der Zee, AGJ Daemen, T J Transl Med Review Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit significant immune responses against their tumor. In this review the knowledge obtained thus far on the interaction of ovarian cancer tumor cells and the immune system is discussed. Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. Based on the increased knowledge on the role of the immune system in ovarian cancer major improvements are to be expected of immunotherapy based treatment of this disease. BioMed Central 2005-09-15 /pmc/articles/PMC1243238/ /pubmed/16164749 http://dx.doi.org/10.1186/1479-5876-3-34 Text en Copyright © 2005 Nijman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Nijman, HW
Lambeck, A
van der Burg, SH
van der Zee, AGJ
Daemen, T
Immunologic aspect of ovarian cancer and p53 as tumor antigen
title Immunologic aspect of ovarian cancer and p53 as tumor antigen
title_full Immunologic aspect of ovarian cancer and p53 as tumor antigen
title_fullStr Immunologic aspect of ovarian cancer and p53 as tumor antigen
title_full_unstemmed Immunologic aspect of ovarian cancer and p53 as tumor antigen
title_short Immunologic aspect of ovarian cancer and p53 as tumor antigen
title_sort immunologic aspect of ovarian cancer and p53 as tumor antigen
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243238/
https://www.ncbi.nlm.nih.gov/pubmed/16164749
http://dx.doi.org/10.1186/1479-5876-3-34
work_keys_str_mv AT nijmanhw immunologicaspectofovariancancerandp53astumorantigen
AT lambecka immunologicaspectofovariancancerandp53astumorantigen
AT vanderburgsh immunologicaspectofovariancancerandp53astumorantigen
AT vanderzeeagj immunologicaspectofovariancancerandp53astumorantigen
AT daement immunologicaspectofovariancancerandp53astumorantigen